Home  |  Contact

Cellosaurus SUM159PT (CVCL_5423)

[Text version]

Cell line name SUM159PT
Synonyms SUM-159-PT; SUM-159PT; SUM 159PT; SUM-159; SUM 159; SUM159; 159 PT; 159PT
Accession CVCL_5423
Secondary accession CVCL_5590
Resource Identification Initiative To cite this cell line use: SUM159PT (RRID:CVCL_5423)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: GrayJW Breast Cancer Cell Line Panel.
Doubling time: 21.73 hours (https://www.synapse.org/#!Synapse:syn2347014).
Microsatellite instability: Stable (MSS) (PubMed=15677628).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: SUM152; Occasionally.
Sequence variations Heterozygous for HRAS p.Gly12Asp (c.35G>A) (PubMed=19593635; PubMed=28889351).
Heterozygous for PIK3CA p.His1047Leu (c.3140A>T) (PubMed=19593635; PubMed=28889351).
TP53 p.Val157_Arg158insLeu (c.472_473ins3) (PubMed=16541312; PubMed=28889351).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*24:02,02:01
HLA-BB*51:01,15:01
HLA-CC*15:02,03:03
Disease Pleomorphic breast carcinoma (NCIt: C5161)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_RA93 (SUM159PT shPARG)
Sex of cell Female
Age at sampling 71Y
Category Cancer cell line
STR profile Source(s): PubMed=25877200; PubMed=28889351

Markers:
AmelogeninX
CSF1PO11
D3S135811,16
D5S81811
D7S82010
D8S117911,13
D13S31712
D16S53911
D18S5112,14
D21S1128
FGA21,22
Penta D9,11
Penta E17
TH016,7
TPOX8,11
vWA16

Run an STR similarity search on this cell line
Web pages https://sumlineknowledgebase.com/?page_id=256
http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/SUM-159.html
https://www.bioivt.com/sum-breast-cancer-cell-lines/
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
Publications

PubMed=10424408; DOI=10.1023/A:1006135331912
Ignatoski K.M.W., Ethier S.P.
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Cancer Res. Treat. 54:173-182(1999)

PubMed=10604729; DOI=10.1038/sj.bjc.6695007
Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A., Kallioniemi O.-P., Ethier S.P.
Molecular cytogenetic analysis of 11 new breast cancer cell lines.
Br. J. Cancer 81:1328-1334(1999)

PubMed=11044355; DOI=10.1054/bjoc.2000.1458
Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Molecular cytogenetic analysis of breast cancer cell lines.
Br. J. Cancer 83:1309-1317(2000)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=23151021; DOI=10.1186/1471-2164-13-619
Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619-619(2012)

PubMed=23401782; DOI=10.1155/2013/872743
Barnabas N., Cohen D.
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Int. J. Breast Cancer 2013:872743-872743(2013)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L., Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

Cross-references
Cell line databases/resources Cell_Model_Passport; SIDM01452
DepMap; ACH-001391
LINCS_HMS; 51083
LINCS_LDP; LCL-2068
Ontologies BTO; BTO:0004928
EFO; EFO_0001241
Biological sample resources BioSample; SAMN03472960
Chemistry resources PharmacoDB; SUM159PT_1510_2019
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-TABM-157
GEO; GSM75170
GEO; GSM217601
GEO; GSM412074
GEO; GSM412089
GEO; GSM412092
GEO; GSM412105
GEO; GSM412114
GEO; GSM412117
GEO; GSM421890
GEO; GSM474278
GEO; GSM474279
GEO; GSM476481
GEO; GSM476482
GEO; GSM476483
GEO; GSM478318
GEO; GSM478319
GEO; GSM478323
GEO; GSM478324
GEO; GSM847434
GEO; GSM847501
GEO; GSM844707
GEO; GSM844706
GEO; GSM967817
GEO; GSM967822
GEO; GSM1008917
GEO; GSM1053735
GEO; GSM1172993
GEO; GSM1214567
GEO; GSM1401652
Other Wikidata; Q54970841
Polymorphism and mutation databases Cosmic; 904389
Cosmic; 1046944
Cosmic; 1136380
Cosmic; 1287924
Cosmic; 1289412
Cosmic; 1460240
IARC_TP53; 24342
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number24